CO-DIAGNOSTICS INC (CODX:NASDAQ)
$4.3 -0.4 (-8.5106%)
Analysed CO-DIAGNOSTICS INC (CODX:NASDAQ) News Sources
Co-Diagnostics Develops Ebola Assay Strategy Following Recent Global Outbreak Alert
19-05-2026
yahoo.com
Co-Diagnostics Develops Ebola Assay Strategy Following WHO Emergency Alert (CODX)
19-05-2026
advfn.com
Co-Diagnostics Announces $3.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
20-05-2026
yahoo.com
Co-Diagnostics Advances Ebola PCR Assay Development Strategy with Joint Venture CoSara
26-05-2026
yahoo.com
CODX Stock Explodes Over 630% In Six Sessions – Retail Traders Bet The Rally Isn’t Over Yet
26-05-2026
stocktwits.com
Top Midday Gainers
26-05-2026
yahoo.com
Co-Diagnostics (CODX) Q4 2025 Earnings Transcript
27-05-2026
fool.com
Is Co-Diagnostics National Security’s Next Diagnostic Pick?
28-05-2026
marketbeat.com
Co-Diagnostics and CoSara Advance Ebola PCR Test Development and Co-Dx™ PCR Point-of-Care Platform Capabilities
02-06-2026
yahoo.com
Co-Diagnostics Advances Latin American Commercialization Strategy for Co-Dx™ PCR Pro® with Mexico Distributor Agreement
11-06-2026
yahoo.com
What is the current price of CO-DIAGNOSTICS INC (CODX:NASDAQ)?
The current price of CO-DIAGNOSTICS INC (CODX:NASDAQ) is $4.3.
CO-DIAGNOSTICS INC (CODX:NASDAQ) absolute price change since previous trading day?
The absolute price change of CO-DIAGNOSTICS INC (CODX:NASDAQ) since the previous trading day is $-0.4.
CO-DIAGNOSTICS INC (CODX:NASDAQ) percentage price change since previous trading day?
The percentage price change of CO-DIAGNOSTICS INC (CODX:NASDAQ) since the previous trading day is -8.5106%.
What is the most recent average sentiment score for CO-DIAGNOSTICS INC (CODX:NASDAQ)?
The most recent average sentiment score for CO-DIAGNOSTICS INC (CODX:NASDAQ) is 70 out of 100.
What is the most recent average sentiment for CO-DIAGNOSTICS INC (CODX:NASDAQ)?
The most recent sentiment for CO-DIAGNOSTICS INC (CODX:NASDAQ) is .
SEC-8K** Filing Available For CO-DIAGNOSTICS INC (CODX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.